Dr David Chen, PharmD
Clinical Pharmacy and Regulatory Affairs — Former MHRA Advisory Panel; current independent practice
Profile last reviewed: 2026-05-20
Dr Chen brings expertise in UK pharmaceutical regulation, having served on an MHRA advisory panel on peptide classification. He reviews our regulatory content, patient-education guides, and ensures compliance with UK advertising standards.
Credentials
- PharmD — Clinical Pharmacy
- Member of the Royal Pharmaceutical Society (MRPharmS)
- Former member of an MHRA advisory panel on peptide classification
Professional registrations
- General Pharmaceutical Council (GPhC): Registered pharmacist
- Royal Pharmaceutical Society: Member (MRPharmS)
GPhC registration is verifiable by name on the GPhC Online Registers. Registration numbers are not republished here, per standard editorial practice on personal-data minimisation.
Role on the editorial board
Lead reviewer for UK regulatory content — Human Medicines Regulations 2012 framing, ‘specials’ supply, advertising rules, MHRA enforcement context, and the UK legal hub. Also reviews patient-education content for compliance with UK advertising standards.
Conflict of interest disclosures
- No equity in pharmaceutical or peptide companies.
- No paid consulting with online prescribing services or peptide retailers.
- Previously served as a panel member for the MHRA on peptide classification guidance; standard public-body disclosures applied.
- Does not own, operate, or advise any peptide clinic.
Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.
Sections reviewed
- All UK Law hub pages (/legal/*)
- ‘Not for human consumption’ claims explainer
- MHRA enforcement page
- Compounded peptides regulatory analysis
- Patient-education content for CAP / BCAP / HMR 2012 compliance
Citation policy
Regulatory claims must trace to UK statute (legislation.gov.uk), MHRA published guidance, NICE technology appraisals, ASA / CAP code, or named case decisions. Where guidance has been superseded, the page either cites the current version or is flagged for editorial review.
The site-wide methodology is documented in our evidence grading methodology and editorial standards.
About the editorial board
Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.
Other reviewers
- Dr Sarah Mitchell, PhD — Pharmacology and Peptide Therapeutics
- Dr James Harrington, MBChB, MRCP — Clinical Endocrinology
- Dr Elena Kowalski, MSc, PhD — Molecular Biology and Immunology